Roivant Secures $2.25B LNP Patent Settlement with Moderna via Genevant and Arbutus

A $2.25 billion global settlement between Genevant Sciences GmbH, Arbutus, and Moderna closes one of the most consequential lipid nanoparticle (LNP) patent disputes in recent memory, and signals that IP exposure around LNP delivery technology remains a live operational risk for any manufacturer or CMO working in this formulation space. Roivant, which holds interests in Genevant and Arbutus, disclosed the settlement alongside its fiscal year 2026 results on May 20, 2026.

Under the terms, Moderna will pay $950 million to Genevant and Arbutus in July 2026, with an additional $1.3 billion contingent on a favorable resolution of Moderna's Section 1498 appeal. The staged payment structure means the full financial outcome remains unresolved, but the settlement ends all pending U.S. and international patent-infringement litigation between the parties. For formulation teams and licensing leads at organizations using LNP platforms, the case reinforces the due-diligence burden when selecting or contracting delivery technology, particularly where foundational patents on ionizable lipids and encapsulation methods remain contested across jurisdictions.

On the clinical side, Roivant reported that brepocitinib received Breakthrough Therapy Designation from the FDA for cutaneous sarcoidosis, based on positive Phase 2 data. A potentially registrational trial in lichen planopilaris enrolled its first subjects in March 2026. Commercial launch of brepocitinib in dermatomyositis is targeted by end of September 2026, with Phase 3 topline data in non-infectious uveitis expected in the second half of calendar year 2026. Manufacturing and supply readiness for a September launch window will require QA and regulatory teams to have CMC packages and any required post-approval commitments aligned well ahead of that date.

IMVT-1402, Immunovant's FcRn antagonist, posted ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% respectively at Week 16 in 170 enrolled participants with difficult-to-treat rheumatoid arthritis who had failed two or more prior advanced therapy mechanisms. The trial's Period 2 randomized phase is ongoing, with the primary endpoint assessing ACR20 maintenance at Week 28. Further program updates are expected in the second half of 2026.

Roivant reported consolidated cash, cash equivalents, and marketable securities of $4.3 billion as of March 31, 2026, which the company states supports runway into profitability. The mosliciguat Phase 2 PHocus study in pulmonary hypertension associated with interstitial lung disease completed enrollment of 135 subjects within one year of first patient dosing, with topline data also expected in the second half of 2026.

The September 2026 brepocitinib launch in dermatomyositis represents the nearest-term manufacturing and regulatory checkpoint against which plant heads and QA directors should be tracking readiness milestones.

Source: GlobeNewswire via Roivant Sciences press release, May 20, 2026. Live conference call and webcast held at 8:00 a.m. ET on May 20, 2026.